# A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

> **NCT07200908** · PHASE3 · RECRUITING · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 172 (estimated)

## Conditions studied

- Chronic Hepatitis D Infection

## Interventions

- **DRUG:** Brelovitug 300 mg
- **DRUG:** Bulevirtide 2 mg and Brelovitug - 300 mg

## Key facts

- **NCT ID:** NCT07200908
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2027-06-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200908, "A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07200908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*